Australis Capital Inc (AUSAF)

[olivernoyes]

Folium Biosciences acquires API license, poised to enter CBD market
Monday October 21, 2019

COLORADO SPRINGS -- Folium Biosciences announced it has acquired an Active Pharmaceutical Ingredient (API) License for CBD Isolate Pharmaceutical CBD (cannabidiol).folium-biosciences-logo

Folium said it is now poised to penetrate the lucrative pharmaceutical market for CBD with its API license, and pharmaceutical grade CBD Isolate produced at Folium Biosciences Europe B.V. will be marketed for pharmaceutical formulations worldwide.

The absence of detectable THC is confirmed through Folium’s state-of-the-art High Performance Liquid Chromatography (HPLC) instruments and laboratory testing equipment.

Folium said the FDA defines API as an active ingredient in a drug product meant to directly affect the "diagnosis, cure, mitigation, treatment or prevention of disease or to affect the structure and function of the body."

Passage of the 2018 Farm Bill was a precursor to a windfall of research into CBD and the minor cannabinoids produced in industrial hemp. Large pharmaceutical companies are now unleashed to research the therapeutic effects of cannabinoids' impact on modern day ills.

Folium Biosciences said its API will place the company in a registry of a select few companies that can provide pharma with the active ingredient for the development CBD-based drugs.

With its network of hemp farms, more than 300K square feet of manufacturing space, and customized extraction equipment, Folium Biosciences said it retains control over the production, manufacture, and distribution of its cannabinoid products, including its pharmaceutical grade CBD.

"The 2018 Farm Bill, which unequivocally legalized hemp, has prompted an enormous amount of research into the nexus between cannabinoids and human health," said Folium Biosciences' CEO Kashif Shan.

"At Folium Biosciences, we're proud to be at the vanguard of this pharmaceutical revolution."

Folium Biosciences is headquartered in Colorado Springs and claims to be the largest vertically integrated producer, manufacturer, and global distributor of hemp derived phytocannabinoids.

Potential B2B partners wanting to learn about Folium Biosciences’ products can visit www.foliumbiosciences.com/order.

https://www.innovationews.com/Folium-Biosciences-acquires-API-license-poised-to-enter-CBD-market/